Panavance Therapeutics Announces Publication of Encouraging

Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migration

Related Keywords

United States , Bochum , Nordrhein Westfalen , Germany , Switzerland , Ruhr , Swiss , Chris Braumann , Jenene Thomas , Greg Bosch , Chemische Industrie , Journal Of Cancer Research , University Of Duisburg , Panavance Therapeutics Inc , Linkedin , University Bochum , Twitter , Clinical Research At Ruhr , University Of Bochum , Cancer Research , Panavance Therapeutics , Vascular Surgery , Clinical Research , Scientific Advisor , Ruhr University Bochum , Cancer Res Clin Oncol ,